NC
CASC

Nexthera Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Nexthera Capital’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-33,333
Closed -$444K – 52
2015
Q4 		$444K Buy
+33,333
New +$574K 0.63% 24

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nexthera Capital's CASC Position: Q1 2016 in Review

Nexthera Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2016, closing a stake of 33,333 shares — an estimated $444K sold.

Nexthera Capital first reported a position in CASC in Q4 2015 and held it in 1 quarter. The position peaked at $444K in Q4 2015. 80 funds tracked by Wall St. Rank hold CASC as of Q1 2016.

  • Nexthera Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Nexthera Capital sold 33,333 Cascadian Therapeutics, Inc. shares in Q1 2016, an estimated $444K.
  • Nexthera Capital first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Nexthera Capital's Cascadian Therapeutics, Inc. position peaked at $444K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2016.

Based on Nexthera Capital's 13F filing for Q1 2016, filed 13 May 2016.